| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/1078-0432.CCR-05-2267 |
| P698 | PubMed publication ID | 16675560 |
| P50 | author | Tetsuya Nakatsura | Q90059095 |
| Toshihiko Torigoe | Q91737677 | ||
| Noriyuki Satō | Q113953738 | ||
| P2093 | author name string | Yasuharu Nishimura | |
| Satoru Senju | |||
| Hideo Baba | |||
| Toru Beppu | |||
| Yoshiaki Ikuta | |||
| Masanori Matsui | |||
| Yoshihiro Yoshitake | |||
| Daiki Fukuma | |||
| Yutaka Motomura | |||
| Michiko Harao | |||
| Hiroyuki Komori | |||
| Kazunori Yokomine | |||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | immunotherapy | Q1427096 |
| P304 | page(s) | 2689-2697 | |
| P577 | publication date | 2006-05-01 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma | |
| P478 | volume | 12 |
| Q40069479 | A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma. |
| Q52689258 | A dual-function epidermal growth factor receptor pathway substrate 8 (Eps8)-derived peptide exhibits a potent cytotoxic T lymphocyte-activating effect and a specific inhibitory activity. |
| Q36456522 | A glypican-3-derived peptide vaccine against hepatocellular carcinoma |
| Q54392858 | A novel tumor-associated antigen, cell division cycle 45-like can induce cytotoxic T-lymphocytes reactive to tumor cells. |
| Q26753195 | Adaptive immunity in the liver |
| Q37313380 | Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican‑3‑derived peptide |
| Q36124808 | Aptamers against Cells Overexpressing Glypican 3 from Expanded Genetic Systems Combined with Cell Engineering and Laboratory Evolution |
| Q35091441 | Aspartate-β-hydroxylase induces epitope-specific T cell responses in hepatocellular carcinoma |
| Q57168005 | Cancer Cell Glycocalyx and Its Significance in Cancer Progression |
| Q47760070 | Cancer Immunotherapy Targeted Glypican-3 or Neoantigens. |
| Q35569528 | Cancer immunotherapy using novel tumor-associated antigenic peptides identified by genome-wide cDNA microarray analyses |
| Q37600523 | Cellular Immune Responses for Squamous Cell Carcinoma Antigen Recognized by T Cells 3 in Patients with Hepatocellular Carcinoma |
| Q38056365 | Cellular immune responses to hepatocellular carcinoma: lessons for immunotherapy |
| Q56890138 | Characteristics of immune response to tumor-associated antigens and immune cell profile in hepatocellular carcinoma patients |
| Q37031710 | Critical analysis of the potential of targeting GPC3 in hepatocellular carcinoma |
| Q27022422 | Database of T cell-defined human tumor antigens: the 2013 update |
| Q40279723 | Dynamic and specific immune responses against multiple tumor antigens were elicited in patients with hepatocellular carcinoma after cell-based immunotherapy |
| Q37477273 | Efficacy of glypican-3-derived peptide vaccine therapy on the survival of patients with refractory ovarian clear cell carcinoma |
| Q89848312 | Engineering T cells for immunotherapy of primary human hepatocellular carcinoma |
| Q38231581 | Engineering α-fetoprotein-based gene vaccines to prevent and treat hepatocellular carcinoma: review and future prospects |
| Q41683191 | Enhancement of antitumor effect by peptide vaccine therapy in combination with anti-CD4 antibody: Study in a murine model |
| Q50927490 | Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma. |
| Q33850655 | Expansion of interferon-gamma-producing multifunctional CD4+ T-cells and dysfunctional CD8+ T-cells by glypican-3 peptide library in hepatocellular carcinoma patients |
| Q35552355 | Expression of Glypican 3 in low and high grade urothelial carcinomas. |
| Q37035025 | Fine-tuning of cell signaling by glypicans |
| Q34000565 | GPC3 expression in mouse ovarian cancer induces GPC3‑specific T cell-mediated immune response through M1 macrophages and suppresses tumor growth |
| Q35181245 | Galectin 9 and PINCH, novel immunotherapy targets of renal cell carcinoma: a rationale to find potential tumour antigens and the resulting cytotoxic T lymphocytes induced by the derived peptides |
| Q39704344 | Generation of functional CD8+ T cells by human dendritic cells expressing glypican-3 epitopes |
| Q57158402 | Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management |
| Q39525572 | Glypican-3 could be an effective target for immunotherapy combined with chemotherapy against ovarian clear cell carcinoma. |
| Q44268931 | Glypican-3 expression in clear cell adenocarcinoma of the ovary |
| Q26772321 | Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma |
| Q84310453 | Glypican-3, a novel prognostic marker of hepatocellular cancer, is related with postoperative metastasis and recurrence in hepatocellular cancer patients |
| Q90012553 | Glypican-3: A New Target for Diagnosis and Treatment of Hepatocellular Carcinoma |
| Q34543102 | Glypican-3: A new target for cancer immunotherapy |
| Q39378285 | Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment |
| Q26827487 | Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma |
| Q33779140 | HCA519/TPX2: a potential T-cell tumor-associated antigen for human hepatocellular carcinoma |
| Q51060418 | HLA-A2-restricted glypican-3 peptide-specific CTL clones induced by peptide vaccine show high avidity and antigen-specific killing activity against tumor cells. |
| Q33895113 | Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies |
| Q36402695 | High-affinity monoclonal antibodies to cell surface tumor antigen glypican-3 generated through a combination of peptide immunization and flow cytometry screening |
| Q37588775 | Identification of HLA-A2 or HLA-A24-restricted CTL epitopes for potential HSP105-targeted immunotherapy in colorectal cancer |
| Q42108269 | Identification of HLA-A2-restricted CTL epitopes of a novel tumour-associated antigen, KIF20A, overexpressed in pancreatic cancer |
| Q43105930 | Identification of SARS-COV spike protein-derived and HLA-A2-restricted human CTL epitopes by using a new muramyl dipeptidederivative adjuvant |
| Q36684407 | Identification of an H2-Kb or H2-Db restricted and glypican-3-derived cytotoxic T-lymphocyte epitope peptide |
| Q36597336 | Identification of glypican-3-derived long peptides activating both CD8(+) and CD4(+) T cells; prolonged overall survival in cancer patients with Th cell response |
| Q92379222 | Immune cell therapy for hepatocellular carcinoma |
| Q35567765 | Immunotherapy for hepatocellular carcinoma: From basic research to clinical use. |
| Q56896669 | Immunotherapy of hepatocellular carcinoma |
| Q51151392 | Improvement of Peptide-Based Tumor Immunotherapy Using pH-Sensitive Fusogenic Polymer-Modified Liposomes. |
| Q39939752 | In vitro generation of cytotoxic and regulatory T cells by fusions of human dendritic cells and hepatocellular carcinoma cells |
| Q93187810 | Inefficient induction of circulating TAA-specific CD8+ T-cell responses in hepatocellular carcinoma |
| Q36759294 | Intratumoral peptide injection enhances tumor cell antigenicity recognized by cytotoxic T lymphocytes: a potential option for improvement in antigen-specific cancer immunotherapy |
| Q34372167 | Large-scale expansion of γδ T cells and peptide-specific cytotoxic T cells using zoledronate for adoptive immunotherapy |
| Q92327875 | Liver Cancer: Current and Future Trends Using Biomaterials |
| Q64058870 | Next-Generation Cancer Immunotherapy Targeting Glypican-3 |
| Q44745178 | Oligomannose-coated liposomes efficiently induce human T-cell leukemia virus-1-specific cytotoxic T lymphocytes without adjuvant |
| Q57594267 | Oxidized and reduced mannan mediated MUC1 DNA immunization induce effective anti-tumor responses |
| Q36888010 | Peptide vaccines for hepatocellular carcinoma |
| Q39630149 | Peptides derived from human insulin‐like growth factor‐II mRNA binding protein 3 can induce human leukocyte antigen‐A2‐restricted cytotoxic T lymphocytes reactive to cancer cells |
| Q37591955 | Phase I clinical trial of peptide vaccination with URLC10 and VEGFR1 epitope peptides in patients with advanced gastric cancer |
| Q33648649 | Plasmodium parasite as an effective hepatocellular carcinoma antigen glypican-3 delivery vector |
| Q26784228 | Potentiality of immunotherapy against hepatocellular carcinoma |
| Q34548226 | Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes |
| Q57294531 | Proteoglycans Are Attractive Biomarkers and Therapeutic Targets in Hepatocellular Carcinoma |
| Q36787608 | Proteoglycans in cancer biology, tumour microenvironment and angiogenesis |
| Q30236010 | Recent advances in hepatocellular carcinoma therapy |
| Q37514736 | Remarkable tumor lysis in a hepatocellular carcinoma patient immediately following glypican-3-derived peptide vaccination: an autopsy case |
| Q34290698 | Significant clinical response of progressive recurrent ovarian clear cell carcinoma to glypican-3-derived peptide vaccine therapy: two case reports. |
| Q41325257 | Soluble HLA-associated peptide from PSF1 has a cancer vaccine potency |
| Q44936405 | Strategies for successful vaccination against hepatocellular carcinoma |
| Q42134157 | Suppression of glypican 3 inhibits growth of hepatocellular carcinoma cells through up-regulation of TGF-β2. |
| Q35841812 | Suppression of postsurgical recurrence of hepatocellular carcinoma treated with autologous formalin-fixed tumor vaccine, with special reference to glypican-3. |
| Q39811302 | The forkhead box M1 transcription factor as a candidate of target for anti-cancer immunotherapy |
| Q39535683 | The immune system in hepatocellular carcinoma and potential new immunotherapeutic strategies |
| Q34528638 | The present status and future prospects of peptide-based cancer vaccines |
| Q42734544 | Trial Watch: Peptide vaccines in cancer therapy |
| Q35894880 | Tumor progression-related transmembrane protein aspartate-β-hydroxylase is a target for immunotherapy of hepatocellular carcinoma |
Search more.